You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 135 No. 2, February 1999 TABLE OF CONTENTS
  Archives
  •  Online Features
  The Cutting Edge: Challenges in Medical and Surgical Therapeutics
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on ISI (13)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Bacterial Infections
 •Dermatology, Other
 •Alert me on articles by topic

Treatment of Refractory Disseminated Mycobacterium abscessus Infection With Interferon Gamma Therapy

Arthur S. Colsky, PhD, MD; Andrew Hanly, MD; George Elgart, MD; Fransisco A. Kerdel, MD
Department of Dermatology and Cutaneous Surgery, University of Miami School of Medicine, Miami, Fla

Arch Dermatol. 1999;135:125-127.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

REPORT OF A CASE

A 60-year-old woman was admitted to the hospital with disseminated Mycobacterium abscessus infection. Her disease had been refractory to conventional antibiotic therapy and she continued to develop painful suppurating abscesses on her trunk and extremities. Her infection followed treatment for essential thrombocytosis, which was diagnosed in September 1993. For this, she initially was treated unsuccessfully with hydroxyurea (Hydrea) and plateletpheresis. She was then treated with phosphorus P 32 and busulfan, which was complicated by the development of a protracted pancytopenia with a white blood cell count at the lowest point of 0.0009x109/L. A bone marrow biopsy specimen showed mild myelodysplasia, and she was treated with filgrastim (Neupogen) and epoetin alfa (Epogen) over a several-month period, with eventual recovery of her blood cell counts to normal by May 1996. In December 1995, while . . . [Full Text of this Article]

THERAPEUTIC CHALLENGE

SOLUTION

COMMENT







HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1999 American Medical Association. All Rights Reserved.